Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PLT012
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilatus Secures FDA Orphan Drug Designation for PLT012 in Liver/Bile Duct Cancer
Details : PLT012 is a CD36 inhibitor, monoclonal antibody candidate, which is being evaluated for the treatment of patients with liver and intrahepatic bile duct cancer.
Product Name : PLT012
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : PLT012
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable